RecruitingNCT05060289

A Prognostic Model for Drug-induced Liver Injury in China

A Prognostic Model for Drug-induced Liver Injury in China : A Multi-center, Prospective Cohort Study


Sponsor

Beijing Friendship Hospital

Enrollment

3,000 participants

Start Date

May 25, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

A prospective, multi-center, non-interventional cohort study is going to conduct to explore the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of Drug-induced liver injury (DILI) in China and screen novel serum markers. A prognostic model incorporating with the novel serum marker(s) for DILI would be established and validated to imporve the prognosis of patients in China .


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with drug-induced liver injury. The study is currently recruiting participants at 13 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(13)

Beijing 302 Hospital

Beijing, Beijing Municipality, China

Beijing Friendship Hospital, Capital Medical University

Beijing, China

Beijing You 'an Hospital, Capital Medical University

Beijing, China

Beijing Ditan Hospital

Beijing, China

Peking University Third Hospital

Beijing, China

The Second Affiliated Hospital of Dalian Medical University

Dalian, China

Qinzhou First People's Hospital

Guangxi, China

Hebei CNPC Central Hospital

Hebei, China

Jiaozuo People's Hospital

Jiaozuo, China

The Second Hospital of Lanzhou University

Lanzhou, China

The Affiliated Hospital of Qingdao University

Qingdao, China

Qinghai People's Hospital

Qinghai, China

Yuncheng Central Hospital

Yuncheng, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05060289


Related Trials